NCBiotech News

Life sciences-related expansions, relocations or new facilities representing almost $4 billion in investment and 4,800 jobs were announced across the state in 2021.

A new national public/private consortium designed to boost the development of gene therapies also holds promise for North Carolina, as a major global leader in cell and gene therapies.

Marken, a global logistics company that serves the pharmaceutical and life sciences sectors, has expanded its headquarters and regional distribution operations in Durham to meet growing demand for shipment of clinical drug supplies, especially cell and gene therapies.

GreenLight Biosciences, which has a growing research and development presence in Research Triangle Park, has announced additional financing on its journey to becoming a publicly traded company

Durham-based Cell Microsystems has received $10 million in financing from life science and venture capital firm Telegraph Hill Partners.

Sheila Mikhail, co-founder and CEO of AskBio and an NCBiotech board member, has been named national Entrepreneur of the Year by Ernst & Young.

Suburban Chicago gene therapy company Jaguar Gene Therapy plans to invest $125.4 million and create 200 jobs by the end of the decade at a new Research Triangle Park manufacturing facility.

Kriya Therapeutics is launching a new division, Kriya Ophthalmology, focused on developing gene therapies for rare and prevalent ocular diseases.

The Durham-based genetics startup BioSkryb has relocated into bigger digs.

UNC's CRISPR Genetic & Epigenetic Screening Center opens Oct. 1, with powerful new technology that received funding support from NCBiotech.

The Retinal Degeneration Fund is spinning out its own Raleigh-based biotech startup, Opus Genetics, aiming at curing blindness after landing $19 million in seed financing.

GreenLight Biosciences, with a growing R&D site in RTP, is the latest local company to go public using a SPAC, to accelerate its development of RNA products for human health and agriculture.

Durham-based gene editing company Precision Biosciences has inked a deal with gene editing company iECURE to advance one of Precision’s drug candidates into Phase 1 clinical studies

Bluebird bio, a Massachusetts-based gene and cell therapy company with operations in North Carolina, will sell its Durham biomanufacturing plant to National Resilience for $110 million as part of a strategic alliance between the two companies.

Kriya Therapeutics is poised to revolutionize gene therapies for highly serious diseases like diabetes and severe obesity after landing a whopping $100 million in capital.